FUSED THIOPHENE AND THIAZOLE DERIVATIVES AS ROR GAMMA MODULATORS

The present invention provides fused thiophene and thiazole derivatives of formula (I), which may be therapeutically useful, more particularly as RORγ modulators; in which R1, R2, R3, R4, R5, R6, R7, X1, X2, L, m, n and ring A have the meanings given in the specification, and pharmaceutically accept...

Full description

Saved in:
Bibliographic Details
Main Authors HOSAHALLI, SUBRAMANYA, BEJUGAM, MALLESHAM, KOTRABASAIAH UJJINAMATADA, RAVI
Format Patent
LanguageEnglish
French
Published 09.07.2015
Subjects
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
Online AccessGet full text

Cover

More Information
Summary:The present invention provides fused thiophene and thiazole derivatives of formula (I), which may be therapeutically useful, more particularly as RORγ modulators; in which R1, R2, R3, R4, R5, R6, R7, X1, X2, L, m, n and ring A have the meanings given in the specification, and pharmaceutically acceptable salts thereof that are useful in the treatment and prevention of diseases or disorders, in particular their use in disease(s) or disorder(s) where there is an advantage in modulating RORγ receptor. The present invention also provides preparation of the compounds and pharmaceutical formulations comprising at least one of the fused thiophene and thiazole derivatives of formula (I), together with a pharmaceutically acceptable carrier, diluent or excipient therefor. La présente invention concerne des dérivés de thiophène et de thiazole fusionnés de formule (I), qui peuvent être thérapeutiquement utiles, plus particulièrement en tant que modulateurs RORγ. Dans ladite formule, R1, R2, R3, R4, R5, R6, R7, X1, X2, L, m, n et le cycle A ont les significations décrites dans la description. L'invention porte également sur leurs sels pharmaceutiquement acceptables utiles dans le traitement et la prévention d'états pathologiques ou de troubles, et en particulier sur leur utilisation dans un ou plusieurs états pathologiques ou troubles pour lesquels il est avantageux de moduler le récepteur RORγ. L'invention concerne également la préparation de composés et de formulations pharmaceutiques comprenant au moins l'un des dérivés de thiophène et de thiazole fusionnés de formule (I), associés à un vecteur, un diluant, ou un excipient pharmaceutiquement acceptable.
Bibliography:Application Number: WO2014IB67408